Splicing inhibitors exploit the preferential sensitivity of spliceosome-compromised leukemic cells to these compounds.<h4>Methods</h4>We studied the effect of the splicing inhibitor E7107 using two UM cell lines and ex vivo cultured SF3B1- and BAP1-mutated primary UM tumor slices. Here, BAP1 is linked to neoplasm.